[144] Greif, Inc. SEC Filing

Rhea-AI Filing Summary

Thermo Fisher Scientific Inc. (TMO) filed a Form 4 on July 1, 2025 disclosing that director Jennifer M. Johnson was credited with 76.54 phantom stock units on June 28, 2025 under the company’s Deferred Compensation Plan for Directors. The units, valued at $408.28 each, convert to common stock on a 1-for-1 basis when the director leaves the board or upon a change of control. After the credit, Johnson holds 474.05 stock-equivalent units, all recorded as direct ownership.

The transaction represents routine deferral of quarterly board retainer fees rather than an open-market purchase or sale. With an estimated market value of roughly $31 thousand, the filing is financially immaterial relative to Thermo Fisher’s multi-billion-dollar market capitalization. No options were exercised, no common shares were sold, and the company’s share count and cash position remain unchanged. The filing nevertheless reinforces incentive alignment by tying a portion of Johnson’s compensation to future shareholder returns.

Insights

Corporate Governance Analyst

TL;DR: Routine deferred-comp acquisition; negligible size, neutral impact.

The Form 4 records quarterly board-fee deferral into 76.54 phantom units, lifting the director’s stake to 474.05 units. Because phantom stock is settled only after service ends, there is no immediate liquidity event or cash flow. The $31k market value is immaterial to both the insider and TMO’s capital structure. From a governance standpoint, continued equity linkage is positive for alignment but not large enough to influence sentiment or valuation. I assign a neutral impact rating.

Portfolio Manager

TL;DR: Insignificant position increase; no trading signal.

Johnson’s phantom stock credit under the director plan is administrative, not opportunistic buying. Volume (76.54 units) is de minimis versus TMO’s average daily volume and implies no informational edge. The filing does not alter supply-demand dynamics or forward fundamentals; therefore, I view the market impact as non-existent and maintain a neutral stance on the shares.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	9000	610946.69	26129971	07/01/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	01/19/2021	Restricted Stock Vesting	Issuer			729	01/19/2021	Compensation
Class A	12/20/2021	Restricted Stock Vesting	Issuer			483	12/20/2021	Compensation
Class A	01/17/2023	Restricted Stock Vesting	Issuer			3445	01/17/2023	Compensation
Class A	01/16/2024	Restricted Stock Vesting	Issuer			3128	01/16/2024	Compensation
Class A	01/16/2025	Restricted Stock Vesting	Issuer			1215	01/16/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)